We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$602M
AUM Growth
-$78.7M
Cap. Flow
-$49.8M
Cap. Flow %
-8.27%
Top 10 Hldgs %
57.8%
Holding
63
New
5
Increased
16
Reduced
14
Closed
15
Avg Time Held
5.2 quarters
Top 10 Avg Time Held
4.3 quarters
Top 20 Avg Time Held
4.6 quarters

Top Buys

Rank Stock Value
1
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$12.7M
2
LRMR icon
Larimar Therapeutics
LRMR
+$8.22M
3
WGS icon
GeneDx Holdings
WGS
+$4.86M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$4.59M
5
KROS icon
Keros Therapeutics
KROS
+$4.2M

Top Sells

Rank Stock Value
1
AUTL icon
Autolus Therapeutics
AUTL
+$12.1M
2
IRON icon
Disc Medicine
IRON
+$11M
3
CKPT icon
Checkpoint Therapeutics
CKPT
+$9.19M
4
IMVT icon
Immunovant
IMVT
+$7.49M
5
SMTI icon
Sanara MedTech
SMTI
+$7.01M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OCUL icon
1
Ocular Therapeutix
OCUL
$1.66B
$91.9M 15.26%
6,480,000
– –
2019 Q1
9 quarters
CMRX icon
2
DELISTED
Chimerix, Inc.
CMRX
$37M 6.15%
4,630,000
+140,000
+3% +$1.16M
2020 Q2
4 quarters
CLDX icon
3
Celldex Therapeutics
CLDX
$2.31B
$32.9M 5.47%
985,000
– –
2020 Q2
4 quarters
BBIO icon
4
BridgeBio Pharma
BBIO
$12.9B
$31.5M 5.24%
517,150
-66,617
-11% -$3.8M
2021 Q1
1 quarter
CDXS icon
5
Codexis
CDXS
$154M
$30.5M 5.06%
1,345,000
-55,000
-4% -$1.19M
2014 Q1
29 quarters
ETON icon
6
Eton Pharmaceutcials
ETON
$1.58B
$29.3M 4.87%
3,692,600
-347,400
-9% -$2.57M
2018 Q4
10 quarters
HROW icon
7
Harrow
HROW
$1.09B
$29.2M 4.85%
3,140,000
+74,584
+2% +$636K
2018 Q3
11 quarters
TARA icon
8
Protara Therapeutics
TARA
$164M
$24.9M 4.14%
2,558,472
– –
2019 Q3
7 quarters
STXS icon
9
Stereotaxis
STXS
$114M
$24.4M 4.05%
2,526,500
– –
2019 Q3
7 quarters
TCON
10
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$16.3M 2.71%
125,919
– –
2020 Q3
3 quarters
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$6.18B
$16.1M 2.67%
1,155,200
+834,274
+260% +$12.7M
2020 Q2
4 quarters
MGNX icon
12
MacroGenics
MGNX
$237M
$15.5M 2.58%
578,150
-88,050
-13% -$2.58M
2019 Q4
6 quarters
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.37B
$14.8M 2.46%
330,222
+33,222
+11% +$1.1M
2020 Q4
2 quarters
FBIO icon
14
Fortress Biotech
FBIO
$70.4M
$13.8M 2.3%
258,333
– –
2020 Q2
4 quarters
XOMA icon
15
DELISTED
Xoma
XOMA
$11.7M 1.94%
343,600
-93,900
-21% -$3.14M
2017 Q1
17 quarters
CYTK icon
16
Cytokinetics
CYTK
$8.73B
$11.5M 1.91%
580,000
– –
2020 Q2
4 quarters
NGNE icon
17
Neurogene
NGNE
$489M
$10.7M 1.77%
57,810
-3,440
-6% -$761K
2019 Q3
7 quarters
AFIB icon
18
DELISTED
Acutus Medical Inc
AFIB
$10.2M 1.69%
599,990
-15,000
-2% -$219K
2020 Q3
3 quarters
KROS icon
19
Keros Therapeutics
KROS
$230M
$9.98M 1.66%
235,000
+77,500
+49% +$4.2M
2021 Q1
1 quarter
VSTM icon
20
Verastem
VSTM
$747M
$9.46M 1.57%
193,750
– –
2020 Q3
3 quarters
PRQR icon
21
ProQR Therapeutics
PRQR
$229M
$9.3M 1.55%
1,380,400
+77,400
+6% +$499K
2021 Q1
1 quarter
STRO icon
22
Sutro Biopharma
STRO
$220M
$9.24M 1.53%
49,690
+15,495
+45% +$3.03M
2020 Q3
3 quarters
ADMS
23
DELISTED
Adamas Pharmaceuticals
ADMS
$8.82M 1.47%
1,670,600
– –
2020 Q2
4 quarters
EPIX icon
24
DELISTED
ESSA Pharma
EPIX
$8.12M 1.35%
284,050
– –
2020 Q2
4 quarters
PCVX icon
25
Vaxcyte
PCVX
$11B
$8.05M 1.34%
357,800
– –
2020 Q3
3 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2021 Portfolio in Review

As of Q2 2021, Opaleye Management held 63 positions worth $602M, down 12% from $681M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opaleye Management withdrew a net $49.8M in Q2 2021, closing 15 positions and reducing 14 holdings. Its most notable exit was Autolus Therapeutics, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Opaleye Management opened a new position in Larimar Therapeutics worth $7.15M.

  • Opaleye Management's largest Q2 2021 buy was Larimar Therapeutics: 727,800 shares worth $7.15M.
  • Opaleye Management added most to Kiniksa Pharmaceuticals in Q2 2021, an estimated $12.7M increase.
  • Opaleye Management's biggest Q2 2021 reduction was BridgeBio Pharma, cutting an estimated $3.8M.
  • Opaleye Management fully exited Autolus Therapeutics in Q2 2021, selling an estimated $12.1M.
  • Opaleye Management's ten largest holdings make up 58% of its $602M portfolio in Q2 2021.
  • Opaleye Management opened 5 new positions and closed 15 in Q2 2021.
  • Opaleye Management's portfolio value fell 12% quarter-over-quarter to $602M.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.